SU1605925A3 - Способ получени замещенного бензамида, или его фармацевтически приемлемых солей, или его сольвата - Google Patents

Способ получени замещенного бензамида, или его фармацевтически приемлемых солей, или его сольвата Download PDF

Info

Publication number
SU1605925A3
SU1605925A3 SU884355470A SU4355470A SU1605925A3 SU 1605925 A3 SU1605925 A3 SU 1605925A3 SU 884355470 A SU884355470 A SU 884355470A SU 4355470 A SU4355470 A SU 4355470A SU 1605925 A3 SU1605925 A3 SU 1605925A3
Authority
SU
USSR - Soviet Union
Prior art keywords
text
colspan
solvate
pharmaceutically acceptable
compound
Prior art date
Application number
SU884355470A
Other languages
English (en)
Inventor
Монкович Иво
Виллнер Дэвид
Original Assignee
Бристоль-Мейерз Сквибо Компани (Фирма)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бристоль-Мейерз Сквибо Компани (Фирма) filed Critical Бристоль-Мейерз Сквибо Компани (Фирма)
Application granted granted Critical
Publication of SU1605925A3 publication Critical patent/SU1605925A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having carbon atoms of carboxamide groups, amino groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/22—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/22—Radicals substituted by singly bound oxygen or sulfur atoms etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Изобретение относитс  к гетероциклическим соединени м, в частности к получению замещенного бензамида ф-лы @ или его фармацевтически приемлемых солей, или его сольвата, которые обладают противорвотным действием. Цель - вы вление более активных соединений. Получение ведут деметилированием 4-амино-[1-азабицикло (2,2,2)окт-3-ил]-5-хлор-2-метоксибензамида. Полученное соединение подвергают реакции с соединением ф-лы L-CH(CH3)-CO-CH3, где L - удал ема  группа, в присутствии основани  с последующим выделением целевого продукта или переводом его в фармацевтически приемлемую соль или в сольват. 2 табл.

Description

Таблица 1
Число зверьков 4
Редактор А.Мотьшь
Составитель В.М кушева Техред Л.Сердюкова
Заказ 3458
Тираж 315
ВНИИПИ Государственного комитета по изобретени м и открыти м при ГКНТ СССР 113035, Москва, Ж-35, Раушска  наб., д. 4/5
Производственно-издательский комбинат Патент, г. Ужгород, ул. Гагарина, tO.I
Таблица 2
Корректор М.Максимишинец
Подписное

Claims (2)

  1. <claim-text>Формула изобретения</claim-text> <claim-text>Способ получения замещенного бен-</claim-text> <claim-text>или его· фармацевтически приемлемых <sup>!</sup> солей, или его сольвата, отличающийся тем, что соединение</claim-text> <claim-text>подвергают деметилированию и полученное соединение формулы</claim-text> <claim-text>10</claim-text> <claim-text>9 ., 1605925</claim-text> <claim-text>подвергают взаимодействию с соедине- где Ь - удаляемая группа,</claim-text> <claim-text>нием формулы в присутствии основания с последующим выделением целевого продукта или переводом его в фармацевтически приемлемую соль или в сольват.</claim-text> <claim-text>Таблица 1</claim-text> <claim-text>Соединение по примеру</claim-text> <claim-text>Н-спиперона</claim-text> <claim-text>замещение</claim-text> <claim-text>ИК</claim-text> <claim-text>нМ</claim-text> <claim-text>Антагонизм к</claim-text> <claim-text>вызванной апоморфином рвоте у собак <sup>?</sup>Н<sub>И</sub> , мг/кг,</claim-text> <claim-text>п.к.</claim-text> <claim-text>Антагонизм к вызванной днсплатином рвоте у хорьков</claim-text> <claim-text>Доза, мг/кг, в.в.
  2. ‘ 2 (число животных 3)</claim-text> <claim-text>Защита,</claim-text> <claim-text>7</claim-text> <table border="1"> <tr><td> 1</td><td> &gt;1000</td><td> &gt;3</td><td> 3</td><td> 95</td></tr> <tr><td> 2</td><td> &gt;1000</td><td> &gt;3</td><td> 3</td><td> 100</td></tr> <tr><td> Метаклопр амид</td><td> 310</td><td> 0,5</td><td> 3*</td><td> 89</td></tr> <tr><td> Ализаприд</td><td> 290</td><td> 0,3</td><td> 3</td><td> 27</td></tr> <tr><td> Клебоприд</td><td> 11</td><td> 0,04</td><td> 3</td><td> 70</td></tr> <tr><td> Домперидон</td><td> 4,1</td><td> 0,2</td><td> 3</td><td> 50</td></tr> </table> <claim-text>*Число зверьков 4 .</claim-text> <claim-text>Таблица 2</claim-text> <table border="1"> <tr><td rowspan="2"> <claim-text>Соединение</claim-text></td><td colspan="2"> <claim-text>Подкожное</claim-text></td><td colspan="2"> <claim-text>введение*&quot;</claim-text></td><td colspan="2"> <claim-text>Пероральное</claim-text></td><td> <claim-text>**</claim-text> <claim-text>введение</claim-text></td></tr> <tr><td> <claim-text>Номер</claim-text></td><td> <claim-text>Доза <sub>у </sub>νπίκτ ·</claim-text></td><td> <claim-text>2</claim-text></td><td> <claim-text>Защита,</claim-text> <claim-text>7</claim-text></td><td> <claim-text>Номер</claim-text></td><td> <claim-text>Доза,</claim-text> <claim-text>мг/кг·</claim-text></td><td> <claim-text>Защита, 7</claim-text></td></tr> <tr><td> <claim-text>1</claim-text></td><td> <claim-text>2</claim-text></td><td> <claim-text>0,084</claim-text></td><td> <claim-text></claim-text></td><td> <claim-text>95</claim-text></td><td> <claim-text>2</claim-text></td><td> <claim-text>0,1</claim-text></td><td> <claim-text>93</claim-text></td></tr> <tr><td> <claim-text></claim-text></td><td> <claim-text>2</claim-text></td><td> <claim-text>0,030</claim-text></td><td> <claim-text></claim-text></td><td> <claim-text>100</claim-text></td><td> <claim-text>-</claim-text></td><td> <claim-text></claim-text></td><td> <claim-text>-</claim-text></td></tr> <tr><td> <claim-text></claim-text></td><td> <claim-text>2</claim-text></td><td> <claim-text>0,010</claim-text></td><td> <claim-text></claim-text></td><td> <claim-text>92</claim-text></td><td> <claim-text>-</claim-text></td><td> <claim-text>-</claim-text></td><td> <claim-text></claim-text></td></tr> <tr><td> <claim-text></claim-text></td><td> <claim-text>2 ·</claim-text></td><td> <claim-text>0,008</claim-text></td><td> <claim-text></claim-text></td><td> <claim-text>46</claim-text></td><td> <claim-text>-</claim-text></td><td> <claim-text>-</claim-text></td><td> <claim-text>-</claim-text></td></tr> <tr><td> <claim-text>Метоклопрамид</claim-text></td><td> <claim-text>4</claim-text></td><td> <claim-text>2,5</claim-text></td><td> <claim-text></claim-text></td><td> <claim-text>92</claim-text></td><td> <claim-text>3</claim-text></td><td> <claim-text>8,5</claim-text></td><td> <claim-text>86</claim-text></td></tr> <tr><td> <claim-text></claim-text></td><td> <claim-text>3</claim-text></td><td> <claim-text>0,8</claim-text></td><td> <claim-text></claim-text></td><td> <claim-text>92</claim-text></td><td> <claim-text>-</claim-text></td><td> <claim-text></claim-text></td><td> <claim-text>—</claim-text></td></tr> <tr><td> <claim-text></claim-text></td><td> <claim-text>4</claim-text></td><td> <claim-text>0,2</claim-text></td><td> <claim-text></claim-text></td><td> <claim-text>58</claim-text></td><td> <claim-text>-</claim-text></td><td> <claim-text>-</claim-text></td><td> <claim-text>-</claim-text></td></tr> <tr><td colspan="2"> <claim-text>Доза соединения за</claim-text></td><td colspan="4"> <claim-text>1 ч до введения цисплатина,</claim-text></td><td> <claim-text></claim-text></td><td> <claim-text></claim-text></td></tr> <tr><td colspan="2"> <claim-text>Доза соединения за</claim-text></td><td> <claim-text>5 мин до</claim-text></td><td colspan="3"> <claim-text>введения цисплатина.</claim-text></td><td> <claim-text></claim-text></td><td> <claim-text></claim-text></td></tr> <tr><td> <claim-text></claim-text></td><td colspan="3">
SU884355470A 1987-05-18 1988-03-18 Способ получени замещенного бензамида, или его фармацевтически приемлемых солей, или его сольвата SU1605925A3 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/051,880 US4820715A (en) 1984-06-28 1987-05-18 Anti-emetic quinuclidinyl benzamides

Publications (1)

Publication Number Publication Date
SU1605925A3 true SU1605925A3 (ru) 1990-11-07

Family

ID=21973929

Family Applications (1)

Application Number Title Priority Date Filing Date
SU884355470A SU1605925A3 (ru) 1987-05-18 1988-03-18 Способ получени замещенного бензамида, или его фармацевтически приемлемых солей, или его сольвата

Country Status (33)

Country Link
US (1) US4820715A (ru)
JP (1) JP2502343B2 (ru)
KR (1) KR880013897A (ru)
AR (1) AR245928A1 (ru)
AT (1) AT399338B (ru)
AU (2) AU621287B2 (ru)
BE (1) BE1003571A5 (ru)
CA (1) CA1303616C (ru)
CH (1) CH678852A5 (ru)
CS (1) CS275840B6 (ru)
CY (3) CY1664A (ru)
DD (1) DD274210A5 (ru)
DE (1) DE3816799C2 (ru)
DK (1) DK151988A (ru)
ES (1) ES2009570A6 (ru)
FI (1) FI882233A (ru)
FR (1) FR2615512B1 (ru)
GB (3) GB2205095B (ru)
GR (1) GR1000631B (ru)
HK (3) HK72592A (ru)
HU (1) HU201731B (ru)
IE (1) IE60707B1 (ru)
IL (1) IL86244A0 (ru)
IT (1) IT1217573B (ru)
LU (1) LU87173A1 (ru)
NL (1) NL8800683A (ru)
NO (1) NO176273C (ru)
PT (1) PT87470B (ru)
SE (2) SE8801845L (ru)
SG (1) SG80592G (ru)
SU (1) SU1605925A3 (ru)
YU (1) YU46448B (ru)
ZA (1) ZA881966B (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4820715A (en) * 1984-06-28 1989-04-11 Bristol-Myers Company Anti-emetic quinuclidinyl benzamides
GB8718345D0 (en) * 1987-08-03 1987-09-09 Fordonal Sa N-substituted benzamides
EP0303445A1 (en) * 1987-08-13 1989-02-15 Walton S.A. Clebopride transdermal patch
JPH02207065A (ja) * 1989-02-07 1990-08-16 Teikoku Chem Ind Corp Ltd ベンズアミド誘導体
AU632387B2 (en) * 1989-12-05 1992-12-24 Marion Merrell Dow Inc. Pyridinium hydrochloride metoclopramide demethylation
US5236931A (en) * 1992-03-26 1993-08-17 A. H. Robins Company, Incorporated 2-substituted benzamide and benzoate derivatives of 3-aminoquinuclidine and 3-quinuclidinol
DE69425970T2 (de) * 1993-06-23 2001-01-18 Chugai Pharmaceutical Co Ltd Benzol-derivate, verwendbar für ischämische erkrankungen
JP3235913B2 (ja) * 1993-07-30 2001-12-04 エーザイ株式会社 アミノ安息香酸誘導体
US5723103A (en) * 1994-12-09 1998-03-03 Vanderbilt University Substituted benzamides and radioligand analogs and methods of use
BR9811676A (pt) * 1997-07-11 2000-09-19 Janssen Pharmaceutica Nv (+) norcisaprida útil para distúrbios mediados por 5-ht3 e 5-ht4
SE0002531D0 (sv) * 2000-07-05 2000-07-05 Active Biotech Ab Immune Enhancement
US6486172B2 (en) 2000-08-18 2002-11-26 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
WO2002016358A2 (en) 2000-08-18 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
WO2002064094A2 (en) * 2001-02-09 2002-08-22 Merck & Co., Inc. 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
PE20021019A1 (es) 2001-04-19 2002-11-13 Upjohn Co Grupos azabiciclicos sustituidos
WO2003018586A1 (en) * 2001-08-24 2003-03-06 Pharmacia & Upjohn Company Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease
JP2005522456A (ja) 2002-02-15 2005-07-28 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー Ｃｎｓ関連障害治療のためのアザビシクロ置換ベンゾイルアミドおよびチオアミド
WO2003072578A1 (en) * 2002-02-20 2003-09-04 Pharmacia & Upjohn Company Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1525M (fr) * 1961-07-25 1962-11-16 Ile De France Médicaments antiémétiques nouveaux.
FR2313935A1 (fr) * 1975-06-10 1977-01-07 Ile De France Nouveaux benzamides substitues, leurs derives et leur procede de preparation
US3966957A (en) * 1972-04-03 1976-06-29 A. H. Robins Company, Incorporated Method for controlling emesis with N-(1-substituted-3-pyrrolidinyl)benzamides and thiobenzamides
GB1507462A (en) * 1974-03-21 1978-04-12 Gallardo Antonio Sa N-heterocyclic substituted benzamides methods for their preparation and compositions containing them
US4189495A (en) * 1974-09-17 1980-02-19 Synthelabo 2-Methoxy-benzamide derivatives
US4039672A (en) * 1975-01-11 1977-08-02 Societe D'etudes Scientifiques Et Industrielles De L'ile-De-France N-(1'-allypyrrolidinyl 2'-methyl) 2-methoxy 4,5-azimido benzamide and its pharmaceutically acceptable salts
US4197243A (en) * 1975-04-02 1980-04-08 Yamanouchi Pharmaceutical Co., Ltd. N-1-Benzyl-3-pyrrolidinyl-4-dimethylamino benzamide derivatives
FI763021A (ru) * 1975-11-03 1977-05-04 Thomae Gmbh Dr K
FR2342064A1 (fr) * 1976-02-26 1977-09-23 Andre Buzas Benzamides 2,5 disubstitues, leurs procedes de preparation et leurs applications therapeutiques
GB1574418A (en) * 1976-11-16 1980-09-03 Anphar Sa Piperidine derivatives
US4207327A (en) * 1977-08-19 1980-06-10 A. H. Robins Company, Inc. N-(4-Pyrazolidinyl)benzamides and their amino precursors
EP0067615B1 (en) * 1981-06-17 1986-01-08 Beecham Group Plc Alkylthio derivatives of azabicyclobenzamides, their preparation and pharmaceutical compositions
CA1183847A (en) * 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide derivatives
JPS5946281A (ja) * 1982-09-09 1984-03-15 Suntory Ltd １置換ピロリチジン誘導体およびその用途
US4593034A (en) * 1984-04-06 1986-06-03 A. H. Robins Company, Inc. 2-alkoxy-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamides and thiobenzamides
US4820715A (en) * 1984-06-28 1989-04-11 Bristol-Myers Company Anti-emetic quinuclidinyl benzamides
US4808624A (en) * 1984-06-28 1989-02-28 Bristol-Myers Company Pharmacologically active substituted benzamides
US4605652A (en) * 1985-02-04 1986-08-12 A. H. Robins Company, Inc. Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes
DE3688296T2 (de) * 1985-03-14 1993-11-04 Beecham Group Plc Arzneimittel zur behandlung von erbrechen.
US4717563A (en) * 1986-03-05 1988-01-05 A. H. Robins Company, Inc. 2-alkoxy-N-(1-azabicyclo(2.2.2)oct-3-yl) benzamides and thiobenzamides in a method for alleviating emesis caused by non-platinum anticancer drugs
GB8718345D0 (en) * 1987-08-03 1987-09-09 Fordonal Sa N-substituted benzamides
EP0311724A1 (en) * 1987-10-16 1989-04-19 Synthelabo Anxiolytic-R-N-(1-azabicyclo[2.2.2]oct-3-yl) benzamides and thiobenzamides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Патент GB 1500105, кл. С 2 С, 1979. *

Also Published As

Publication number Publication date
CS275840B6 (en) 1992-03-18
GR880100329A (en) 1989-02-23
FI882233A0 (fi) 1988-05-12
DE3816799C2 (de) 1996-07-04
IT8820550A0 (it) 1988-05-12
GB2205095A (en) 1988-11-30
AU1311588A (en) 1988-11-24
SE8808452A (sv) 1988-11-19
AU640300B2 (en) 1993-08-19
IT1217573B (it) 1990-03-30
GR1000631B (el) 1992-09-11
CS8801469A2 (en) 1990-09-12
AR245928A1 (es) 1994-03-30
GB2205095B (en) 1992-02-26
HK72492A (en) 1992-10-02
CA1303616C (en) 1992-06-16
CY1664A (en) 1993-05-14
PT87470A (pt) 1989-05-31
GB8805870D0 (en) 1988-04-13
YU55588A (en) 1989-08-31
GB2243833A (en) 1991-11-13
IL86244A0 (en) 1988-11-15
PT87470B (pt) 1992-09-30
DK151988A (da) 1988-11-19
HU201731B (en) 1990-12-28
GB9113070D0 (en) 1991-08-07
FR2615512B1 (fr) 1994-02-18
GB9113068D0 (en) 1991-08-07
ZA881966B (en) 1989-11-29
IE60707B1 (en) 1994-08-10
AU1032992A (en) 1992-03-12
FR2615512A1 (fr) 1988-11-25
HUT47238A (en) 1989-02-28
DK151988D0 (da) 1988-03-18
SG80592G (en) 1992-10-02
GB2243832A (en) 1991-11-13
CY1665A (en) 1993-05-14
YU46448B (sh) 1993-10-20
NO881206D0 (no) 1988-03-18
GB2243833B (en) 1992-02-26
DD274210A5 (de) 1989-12-13
CH678852A5 (ru) 1991-11-15
CY1662A (en) 1993-05-14
IE880704L (en) 1988-11-18
FI882233A (fi) 1988-11-19
LU87173A1 (fr) 1988-11-17
NO881206L (no) 1988-11-21
SE8801845L (sv) 1988-11-19
NO176273C (no) 1995-03-08
JPS63313757A (ja) 1988-12-21
KR880013897A (ko) 1988-12-22
US4820715A (en) 1989-04-11
SE8801845D0 (sv) 1988-05-17
HK72592A (en) 1992-10-02
ES2009570A6 (es) 1989-10-01
DE3816799A1 (de) 1988-12-08
NL8800683A (nl) 1988-12-16
ATA69888A (de) 1994-09-15
NO176273B (no) 1994-11-28
BE1003571A5 (fr) 1992-04-28
GB2243832B (en) 1992-02-26
AU621287B2 (en) 1992-03-12
HK72392A (en) 1992-10-02
JP2502343B2 (ja) 1996-05-29
AT399338B (de) 1995-04-25

Similar Documents

Publication Publication Date Title
SU1605925A3 (ru) Способ получени замещенного бензамида, или его фармацевтически приемлемых солей, или его сольвата
US4605652A (en) Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes
US4863919A (en) Method of enhancing memory or correcting memory deficiency with arylamido(and arylthiomido)-azabicycloalkanes
IE47798B1 (en) Substituted ortho-anisamides,methods of preparing them,compositions containing them and their application as psychotropic agents
HUT58322A (en) Process for producing new n-(3-hydroxy-4-piperidinyl)-dihydro-benzofurane-, -dihydro-2h-penzopyrane- and -dihydro-benzodioxine-carboxamide derivatives and pharmaceutical compositions containing them
HUT45503A (en) Process for producing alpha-alkyl-(4-amino-3-quinolinyl)-methanols, 1-/4-(aralkyl-amino)-3-quinolinyl/-alkanones and pharmaceutics comprising these compounds as active ingredient
HUT48589A (en) Process for production of new derivatives of substituated n-/1-hydroxi-4-piperidinil/-benzamid
US4717563A (en) 2-alkoxy-N-(1-azabicyclo(2.2.2)oct-3-yl) benzamides and thiobenzamides in a method for alleviating emesis caused by non-platinum anticancer drugs
US3262852A (en) Vasodilator and anti-anginose com- pounds containing methoxy benzyl piperazines and method of using the same
HUT46536A (en) Process for producing antianxietive pharmaceutical compositions
SU1355122A3 (ru) Способ получени производных бензамида
DK196688A (da) Bicykliske forbindelser og fremgangsmaade til fremstilling deraf
HUT47531A (en) Process for producing amide derivatives and pharmaceuticals comprising such compounds
EP0306345B1 (en) 2-alkoxy-n-(1-azabicyclo(2.2.2)-oct-3-yl) benzamides and thiobenzamides having an antischizophrenic activity
ES2273838T3 (es) Composiciones fermaceuticas que contienen derivados de aminotiazol para el tratamiento de disfunciones motoras colonicas.
IL92233A0 (en) 1,2,3,4-tetrahydro-1,9-acridinediamines,a process for their preparation and their use as pharmaceutical compositions
ES2028838T3 (es) Procedimiento para la obtencion de nuevos derivados de 4,5-hidro-oxazoles.
HUT45518A (en) Process for producing 1,5-benzothiazepine derivatives and pharmaceutics comprising these compounds
HUT67032A (en) Novell 9-aminotetrahydroacridines, pharmaceutical compositions comprising them, and process for their production
US6566396B2 (en) Antitussive/antihistaminic compositions
HUT53107A (en) Process for producing fusioned heterocyclic derivatives of 1,2,3,4-tetrahydroacridine and pharmaceutical compositions comprising such compounds
US3769317A (en) Novel ester derivatives of phenylpropanolamine
HU186087B (en) Process for producing cystine derivatives
NO831040L (no) Enantiomerer av substituerte fenylazacykloalkaner og fremgangsmaate for deres fremstilling
KR820001020B1 (ko) 4-아미노 5-알킬설포닐 오르토-아니스 아미드 유도체의 제조방법